MDNAF.US Medicenna Therapeutics Corp

Healthcare Biotechnology USA Stocks
0.2550 USD
Close of Nov 16, 2026
0.2290 1.30
Market cap
USD 23.5M
P/E
-
P/B
21.38x
ROE
-1,215.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is MDNAF.US undervalued?

Graham number

The Graham number of Medicenna Therapeutics Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Medicenna Therapeutics Corp fundamental analysis

No fundamental analysis for Medicenna Therapeutics Corp yet.

Medicenna Therapeutics Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Medicenna Therapeutics Corp

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113,…

Full company profile